tbuckley/cabot-search huggingface dataset:
PMO-237 Prebotics as primary prevention of Crohn's disease: impact on luminal microbiology and elevated faecal calprotectin is greater in healthy siblings than in patients: Abstract PMO-237 Table 1
Authors: C R Hedin, P Louis, F Farquharson, S McCartney, A J Stagg, J O Lindsay, K Whelan
Journal: Gut (2012)

<h3>Introduction</h3> Inflammation in Crohn9s disease (CD) is driven by the intestinal microbiota, however, microbial manipulation with prebiotics is ineffective in treating active disease.<sup>1</sup> Siblings of patients are at risk of developing CD, and some share aspects of the CD phenotype including raised faecal calprotectin (FC) and dysbiosis. Prebiotics may alter these risk markers. <h3>Methods</h3> Patients with inactive CD (n=19, CD activity index &lt;150) and 12 unaffected siblings ingested 15 g/d of fructo-oligosaccharide/inulin (FOS) for 3 weeks. FC (enzyme-linked immunosorbant assay) and faecal microbiota (quantitative PCR targeting 16S ribosomal RNA (rRNA) genes, quantified relative to representative bacterial 16S rRNA genes) were measured at baseline and follow-up. Non-parametric statistical analyses were performed, and values presented as medians. <h3>Results</h3> In patients and siblings, Bifidobacteria and <i>Bifidobacterium longum</i> increased post-FOS. In siblings but not patients, <i>Bifidobacterium adolescentis</i> and <i>Roseburia</i> spp. also increased (Abstract PMO-237 table 1). Compared with patients, siblings had a greater median percentage point change in Bifidobacteria (+14.6% vs +0.4%, p=0.028), <i>B adolescentis</i> (+1.1% vs 0.0% p=0.006) and <i>Roseburia</i> spp. (+1.5% vs −0.1% p=0.004). Of those with raised FC at baseline, it decreased post-FOS in only 7/19 patients (37%), compared with 4/5 (80%) siblings (p=0.142). The change in FC was significantly negatively correlated with baseline FC in siblings (r=−0.715, p=0.009) but positively correlated with baseline FC in patients (r=+0.352, p=0.140). <h3>Conclusion</h3> In contrast to inflamed CD,<sup>1</sup> a prebiotic effect with FOS occurs to a limited extent in non-inflamed CD, and also occurs, more markedly, in at-risk siblings. Furthermore, FC decreased in siblings post-FOS, but did not change significantly (and even tended to rise) in patients with inactive CD. Prebiotics may best be employed in disease prevention rather than treatment. <h3>Competing interests</h3> C Hedin: Grant/Research Support from: Clinical Research Fellow funded by Core charity, P Louis: None declared, F Farquharson: None declared, S McCartney: None declared, A Stagg: None declared, J Lindsay: None declared, K Whelan: None declared. <h3>Reference</h3> 1. <b>Benjamin JL</b>, Hedin CR <i>et al.</i><i>Gut</i> 2011;<b>60</b>:923–9.
PRESSURES EXERTED BY COMMERCIALLY AVAILABLE LOWER LIMB COMPRESSION GARMENTS
Authors: J Hill, G Howatson, K van Someren, S Davidson, C Pedlar
Journal: British Journal of Sports Medicine (2014)

Background Commercially available compression garments (CGs) enhance recovery from exercise in some, but not all studies. It has been suggested that the minimum physiologically effective pressure is 17.3 mmHg at the lower leg decreasing to 15.1 mmHg at the thigh (Watanuki and Murata, 1994). CGs are usually fitted using a generalised sizing system based on height and mass, potentially causing variability in the pressure exerted by the garment. Objective We aimed to quantify the pressure, and the variability in pressure, exerted on the leg by CGs fitted according to the manufacturers instructions. Participants 50 healthy, physically active individuals (n=26 male, n=24 female; age 18–65years) volunteered to participate. Design Participants were fitted with CGs according to manufacturers guidelines. The compressive force of the garments was measured in participants standing in the anatomical position including: the medial aspect of the calf at the site of maximal girth and at the midpoint of the femur measured between the inguinal crease and the superior aspect of the patella, of the lower limb. Data were compared to target pressure values. Results Pressure fell short of target values by 3% and 20% at the calf and by 34% and 47% at the thigh for males and females respectively. Figure 1 Box plots representing the mean, standard deviation, upper and lower quartiles for pressure exerted at the calf and thigh for males and females and compared to the target pressure suggested by Watanuki and Murata (1994). Conclusion Many individuals may not be experiencing an adequate pressure from CG (Figure 1); this might explain the inconsistency within the literature regarding CG and recovery. Future research should measure and control for actual pressure exerted by the garment.
Features associated with thought disorder in manic patients at 2-4-year follow-up
Authors: L S Grossman, M Harrow, J R Sands
Journal: American Journal of Psychiatry (1986)

The authors assessed 47 formerly hospitalized manic patients for thought disorder 2-4 years after discharge and studied the relationship between thought disorder and other major clinical variables. Fourteen (30%) of the manic patients showed severe positive thought disorder 2-4 years after hospitalization. Partial correlations and multiple regression analyses indicated that thought disorder at follow-up was most closely related to the presence of manic behavior and psychosis. It was also more frequent in manic patients with poor posthospital functioning and in manic patients with multiple previous manic episodes or a more chronic course of illness.
Effects of Phenylbutazone in Gout
Authors: Harold P. Johnson, Ephraim P. Engleman, Peter H. Forsham, Marcus A. Krupp, Thomas W. Green, Alan Goldfien
Journal: New England Journal of Medicine (1954)

PHENYLBUTAZONE (3, 5-dioxo-l, 2–diphenyl4-n-butyl-pyrazolidin sodium) is a pyrazolon derivative with anti-inflammatory and analgesic properties.1 Its formula is as follows: Success with this drug in the treatment of gout has previously been reported by Gutman and Yü,2 by Kuzell et al.,3 , 4 and by Steinbrocker and his associates.5 In the past year we have observed its effects in 26 male adult patients with gouty arthritis, of whom 10 had acute arthritis and 16 chronic joint disease.MethodsPatients with acute arthritis were seen on an outpatient basis; patients with chronic diseases were hospitalized, when indicated, on the medical wards at the Veterans . . .
LONG-TERM EFFICACY OF TREAT AND REPAIR STRATEGY FOR ATRIAL SEPTAL DEFECT WITH PULMONARY ARTERY HYPERTENSION
Authors: Teiji Akagi, Yoichi Takaya, Yasufumi Kijima, Koji Nakagawa, Hiroki Oe, Hiroshi Ito, Shunji Sano
Journal: Journal of the American College of Cardiology (2016)
Effect of maximal sprints performed with ball on anaerobic power and performance of footballers
Authors: A Kamar
Journal: British Journal of Sports Medicine (2011)

The effect of sprints performed with a ball on the anaerobic power and performance was examined after RAST (Running-Based Anaerobic Sprint Test) that measures the anaerobic power was applied to 19 male footballers whose Mean age was 18± 1 y, height 74±6 cm, body mass 65.7±5.6 kg and maxVO 2 53±5 ml/kg/min firstly in the normal procedure and then in the form of sprint with ball. Sprinting with the ball caused the anaerobic power average of the experiment group to decline by 23 % (P&lt;0.001). While the average value was 5.5±0.4 s (501±97 W) in the normal procedure, this value was 6.0± 0.4 s (388±83 W) in the one performed with the ball. When 6 sprints of subjects performed with ball and without ball were examined, the least loss of average power was observed in the 3rd runs (−20%). As for the maximum power loss, it was detected in the average of 5th runs (−28%), (P&lt;0.001). When the fatigue index of the subjects was analysed, value obtained in the normal procedure without a ball was 7.5±2.4 W/s and the average value of the practice with ball was 5.8±2.0 W/s (P&lt;0.001). In the study, sprint distance was analysed in divisions of 5 m each and acceleration change of running within this distance was examined. While average acceleration naturally varied in the five meter parts of the sprint run of a total 35 m, the highest acceleration of both the normal procedure and the practice with ball was detected between 20th and 25thm (P&lt;0.001). RAST (P&lt;0.01) and with ball RAST (P&lt;0.05) are correlated Vertical Jump and Standing Long Jump.
AN AGE- AND SEX-SPECIFIC PERIPHERAL BLOOD GENE EXPRESSION SCORE CORRELATES WITH FUTURE CARDIOVASCULAR EVENTS: INSIGHTS FROM THE PROMISE TRIAL
Authors: Deepak Voora, Adrian Coles, Kerry Lee, Udo Hoffmann, James Wingrove, Brian Rhees, Lin Huang, Susan Daniels, Mark Monane, Steven Rosenberg, Daniel Mark, Svati Shah, William Kraus, Geoffrey Ginsburg, Pamela Douglas
Journal: Journal of the American College of Cardiology (2016)
345 PERSISTENT HEPATITIS C VIRUS (HCV) INFECTION IMPAIRS HCV-SPECIFIC CYTOTOXIC T CELL REACTIVITY THROUGH Mcl-1/Bim IMBALANCE DUE TO CD127 DOWN-REGULATION
Authors: J.R. Larrubia, M.U. Lokhande, S. García-Garzón, J. Miquel, A. González-Praetorious, E. Sanz-de-Villalobos
Journal: Journal of Hepatology (2013)
AB0326 Severity index for rheumatoid arthritis and its association with healthcare costs and biologic therapy use in turkey
Authors: O. Baser, E. Baser, A. Altinbas, A. Burkan
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To apply a validated claims-based severity index for rheumatoid arthritis (SIFRA) to prevalent RA groups in Turkey to determine the effects of RA severity on healthcare costs and biologic use. <h3>Methods</h3> Using medical and pharmacy claims and eligibility data from the Turkish national health insurance database MEDULA for RA patients in Turkey (01JUN2009-31DEC2011), prevalent RA patients age 18-99, with two RA diagnoses ≥60 days apart and continuously enrolled 1 year pre- and post-index date (first RA claim 01JUN2009-31DEC2010) were analyzed. SIFRA was calculated for the baseline period. Healthcare costs and biologic use were examined for the follow-up period. Chi-square tests were used to find SIFRA score and outcome association. Generalized linear models were used to determine costs, and multivariate logistic regression were used to determine SIFRA effect. <h3>Results</h3> 1,920 RA patients were identified. Mean SIFRA score was 14.21, and 7.05 (49.57%) included clinical and functional status variables, medications: 6.32 (44.47%); radiology and laboratory results: 0.48 (3.40%), and extra-articular manifestation: 0.32 (2.25%). Controlling for age, gender, region, and comorbidity index, high SIFRA tercile patients were 5.16 times more likely to be prescribed biologics (p&lt;0.001, CI: 3.46-7.69), and incurred higher costs €2,091 (p&lt;0.001, CI: €1,557-€2,625) than those in the low SIFRA tercile. <h3>Image/graph</h3> <h3>Conclusions</h3> RA severity varies in Turkey, and is a determinant of healthcare costs and biologic therapy use. Biologic use positively correlated with severity score. Future comparative effectiveness studies in RA treatment should include severity scores. <h3>Disclosure of Interest</h3> None Declared
Dynamic Extrathoracic Airway Obstruction
Authors: Deepak Pradhan, Kenneth Berger
Journal: New England Journal of Medicine (2012)

A 53-year-old woman with a history of traumatic laryngeal fracture in childhood was referred for evaluation of excessive daytime somnolence. Inspiratory stridor was evident on physical examination. A spirometric flow-volume loop (Panel A) revealed an abnormal inspiratory airflow plateau (dashed line) and inspiratory flow oscillations (arrowhead), a pattern suggesting the presence of a dynamic extrathoracic airway obstruction (a normal flow-volume loop is shown in orange). Polysomnography confirmed that intermittent dynamic limitation of inspiratory flow was resulting in snoring and sleep disruption. Laryngoscopy revealed redundant supraglottic mucosa of the aryepiglottic folds (Panel B, arrows) that fluttered during inhalation and exhalation (Video). . . .
1162 RIBAVIRIN DOSE MODIFICATION IN TREATMENT-NAIVE AND PREVIOUSLY TREATED PATIENTS WHO RECEIVED TELAPREVIR COMBINATION TREATMENT: NO IMPACT ON SUSTAINED VIROLOGIC RESPONSE IN PHASE 3 STUDIES
Authors: M.S. Sulkowski, S. Roberts, N. Afdhal, P. Andreone, M. Diago, S. Pol, F. Poordad, S. Zeuzem, L. Bengtsson, D. Luo, J. Witek, N. Adda
Journal: Journal of Hepatology (2012)
Identification of a set of eight proteins able to predict the response to methotrexate/etanercept in rheumatoid arthritis patients
Authors: A. Obry, P Cosette, P Chan Tchi Tsong, J Siemowski, P Morel, C Dauly, O Boyer, P Fardellone, R-M Flipo, C Marcelli, X Le Loët, T Lequerré, O Vittecoq
Journal: Annals of the Rheumatic Diseases (2012)

<h3>Background</h3> The number of biologic agents in rheumatoid arthritis (RA) is continuously increasing. However, clinicians observe that around 30–40% of treated patients fail to respond to tumour necrosis factor α blocking agents. One way to optimise the drug prescription is to identify predictive markers of drug responsiveness. <h3>Objectives</h3> To identify a combination of proteins whose expression profile would predict the RA patients responses to the association of methotrexate (MTX) and etanercept (ETA). <h3>Methods</h3> A set of 10 patients with active RA (average age: 54±16 years old, RA duration: 9±9 years, MTX: 18±3 mg/week, DAS28: 5.5±1.0) was treated by a subcutaneous injection of ETA (50 mg/week). The clinical efficacy of these drugs was evaluated with the DAS28 score after 3, 6 and 12 months of treatment according to the EULAR response criteria. For proteomic analysis, a blood sample was carried out in patients prior to the first injection in order to extract peripheral blood mononuclear cells (PBMC). A relative quantification of protein expression from seven samples of PBMC was performed by mass spectrometry, after labelling with stable isotopes (Isobaric Tags for Relative and Absolute Quantification: iTRAQ). Protein identification and differential analysis between the samples from responders (R) and non-responders (NR) were made with the Spectrum Mill software (Agilent). The statistical treatment using iQuantitator has enabled the relative protein quantification for each patient. From five others samples of PBMC, a complementary approach based exclusively on mass spectrometry was implemented (the ‘label free approach’). ‘Label-free’ quantification is based on extracted ion chromatograms to determine the differential expression. The differential analysis was achieved with SIEVE (Thermofisher), a label-free dedicated software to compare LC/MS data from LTQ Orbitrap (Thermofisher) analysis. <h3>Results</h3> Among the 10 patients, 6 out of 10 were classified as R. When merging the two independent experimental approaches, the authors got consistent results for eight overexpressed proteins and two underexpressed proteins among all patients responding to treatment. <h3>Conclusions</h3> For the first time, the authors identified a proteomic signature from PBMC able to predict MTX/ETA response. These proteins would thus represent valuable candidates for biomarkers of response to this treatment option that should be validated on a larger population. In addition, among the identified proteins, several proteins are also present in plasma, offering the possibility to explore their predictive value by ELISA tests.
E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma.
Authors: D. H. Lawson, S. J. Lee, A. A. Tarhini, K. A. Margolin, M. S. Ernstoff, J. M. Kirkwood
Journal: Journal of Clinical Oncology (2010)

8504 Background: Previous investigations suggested that GM-CSF might be effective in adjuvant therapy of melanoma. Methods: A prospective, randomized, placebo-controlled, phase III trial was conducted by ECOG, SWOG, and CALGB. Eligible patients had completely resected stages IIIB, IIIC, IV or mucosal melanoma. Patients were randomized to receive either GM-CSF 250 mcg or placebo SC daily for 14 consecutive days every 28 days for one year. The primary endpoint was overall survival (OS); with > 800 patients there is 80% power to detect a 33% increase in median survival from 40 months (mos) to 53.3 mos based on a log-rank test with 2-sided type 1 error of 0.05. A second endpoint was disease free survival (DFS), with 82.5% power to detect a 25% increase from 11 to 13.75 mos. The study called for unblinding after either full information (400 deaths) or 30 months after accrual was completed. The study was unblinded for time elapsed in April, 2009. Results were updated in September, 2009, with 330 deaths, and will be updated again in April, 2010. Results: Between December 29, 1999 and October 31, 2006 815 patients enrolled. As of this report 735 are confirmed eligible. Median OS is 59.8 mos (95% CI 45.3,−) for the placebo arm vs. 72.1 mos (CI 50.9,−) for the GM-CSF arm (p = 0.551, hazard ratio 0.935). Median DFS is 8.8 mos (CI 7.2,12.2) for placebo vs. 11.8 mos (CI 10.2,−) for GM-CSF (p = 0.034, hazard ratio 0.827). Toxicity was consistent with known effects of GM-CSF. Conclusions: Adjuvant GM-CSF improves DFS of patients with completely resected high-risk melanoma with minimal toxicity. OS improvement is less and does not achieve statistical significance. This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, MD, Chair) and supported in part by Public Health Service Grants CA23318, CA66636, CA21115, CA39229, CA32102, CA20319, CA31946, CA04326 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genzyme Genzyme
P-Glycoprotein Expression and AIDS-Related Kaposi's Sarcoma
Authors: G. SCHWARTSMANN, C.T. CERSKI, E. SANDER, E. SPRINZ, M. KRONFELD
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article P-Glycoprotein Expression and AIDS-Related Kaposi's Sarcoma Get access G. SCHWARTSMANN, G. SCHWARTSMANN Setor de Oncologia, Hospital de Clinicas de Porto Alegre, Universidade Federal, do Rio Grande do SulBrazil Search for other works by this author on: Oxford Academic PubMed Google Scholar C.T. CERSKI, C.T. CERSKI Setor de Oncologia, Hospital de Clinicas de Porto Alegre, Universidade Federal, do Rio Grande do SulBrazil Search for other works by this author on: Oxford Academic PubMed Google Scholar E. SANDER, E. SANDER Setor de Oncologia, Hospital de Clinicas de Porto Alegre, Universidade Federal, do Rio Grande do SulBrazil Search for other works by this author on: Oxford Academic PubMed Google Scholar E. SPRINZ, E. SPRINZ Setor de Oncologia, Hospital de Clinicas de Porto Alegre, Universidade Federal, do Rio Grande do SulBrazil Search for other works by this author on: Oxford Academic PubMed Google Scholar M. KRONFELD M. KRONFELD Setor de Oncologia, Hospital de Clinicas de Porto Alegre, Universidade Federal, do Rio Grande do SulBrazil Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 22, 15 November 1989, Pages 1755–1756, https://doi.org/10.1093/jnci/81.22.1755 Published: 15 November 1989
Inhibition of iNOS augments cardiovascular action of noradrenaline in streptozotocin-induced diabetes
Authors: X CHENG, X CHENG, K KUO, C PANG
Journal: Cardiovascular Research (2004)

Objective: The aim was to determine if inducible nitric oxide synthase (iNOS) contributes to depressed cardiovascular function at the acute phase of streptozotocin-induced diabetes.
FRI0267 The influence of anti-malarial drugs (hydroxychloroquine and quinacrine) on the initiation of interferon-alfa production through tlr-9 pathway
Authors: O. Jin, X. Zhang, Q. Li, L. Fang, H. Huang, Z. Liao, Q. Wei, Z. Lin, D. Lin, J. Gu
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Toll-like receptor 9 (TLR-9) can recognize nucleic acids especially DNA segments, plays an important role in innate immunity. Recently, it has been found that TLR-9 also involves in the recognition of self DNA fragments, initiates the autoimmune response with the production of interferon-alfa (IFN-α) which is the central cytokine in Systemic lupus erythematosus (SLE). Anti-malarial drugs such as Hydroxychloroquine (HCQ) and quinacrine (Qn) are commonly used in the treatment of SLE, with the combination of glucocorticoid. However, their mechanisms are still unclear. Recent studies imply that these drugs may influence TLR pathway. <h3>Objectives</h3> To evaluate the influence of anti-malarial drugs ( HCQ and Qn ) on the initiation of IFN-α production through TLR-9 pathway, with or without combination with glucocorticoid. <h3>Methods</h3> Freshly isolated PBMCs of healthy donors were stimulated with the TLR-9 agonist CpG oligodeoxynucleotides (CpG-A ODN)-2216, then incubated with different kinds of anti-malarial drugs ( HCQ and Qn or both) and / or different doses of glucocorticoid (hydrocortisone). The changes in the expression of IFN-α were detected by real time PCR. <h3>Results</h3> (1). Hydroxychloroquine or quinacrine alone or combined together significantly reversed the elevation of IFN-α caused by ODN 2216 (Qn (p=0.047), HCQ (p=0.047), Qn and HCQ (p=0.046)). (2). When combined with low (10-5 M) or middle (10-4 M) dose of hydrocortisone, HCQ or Qn or both significantly revised the elevation of IFN-α caused by ODN 2216 ((low dose: Qn (p=0.034), HCQ (p=0.032), Qn and HCQ (p=0.036), middle dose: Qn (p=0.028), HCQ (p=0.024), Qn and HCQ (p=0.028)), which could not be revised by glucocorticoid alone (each p&gt;0.05). (3). When combined with high dose (10-3 M) hydrocortisone which could significantly promote the expression of IFN-α (p=0.032&lt;0.05), only HCQ could significantly revise the elevation of IFN-α caused by ODN 2216 (p&lt;0.05). <h3>Conclusions</h3> (1). Anti-malarial drugs (HCQ Qn) hamper the critical pathogenesis of lupus that TLR-9 recognition of nucleotides (ODN 2216) elevates the IFN-α expression in PBMCs.(2). The combination with anti-malarial drugs (HCQ Qn) seem to be a good choice to help low or middle dose glucocorticoid to achieve a better disease control by inhibiting IFN-α, which cannot be decreased by glucocorticoid alone. (3). Only HCQ could revise the elevation of IFN-α caused by ODN 2216 in case of using high dose glucocorticoid. <h3>Acknowledgements</h3> This study was supported by the grant for the scientific research foundation of ministry of education in China (20090171120090). <b>Disclosure of Interest</b>: None Declared
THE PULMONARY VASCULAR RESISTANCE AND PULMONARY VASCULAR RESISTANCE TO SYSTEMIC RESISTANCE RATIO BUT NOT DIASTOLIC PULMONARY GRADIENT, MAY PREDICT SURVIVAL IN PATIENTS WITH PULMONARY HYPERTENSION: INSIGHTS FROM A SINGLE-CENTER STUDY
Authors: Cihangir Kaymaz, Selcuk Ozturk, Ozgur Y. Akbal, Nertila Poci, Tugba Aktemur, Fatih Yilmaz, Hacer Tokgoz, Sevim Turkday, Aykun Hakgor, Nihal Ozdemir
Journal: Journal of the American College of Cardiology (2015)